Smart Immune et CELL
Smart Immune et CELLforCURE by SEQENS s'associent pour industrialiser la production des lots cliniques de SMART101
December 03, 2024 00:00 ET | Smart Immune
COMMUNIQUÉ DE PRESSE | Paris, France - 3 décembre 2024 Smart Immune, société de biotechnologie en stade clinique, et CELLforCURE by SEQENS, entreprise de développement et de fabrication en...
Smart Immune and CEL
Smart Immune and CELLforCURE by SEQENS Partner to Industrialize SMART101 Clinical Batches Manufacturing
December 03, 2024 00:00 ET | Smart Immune
PRESS RELEASE | Paris, France – December 3, 2024 Smart Immune, a clinical-stage biotechnology company, and CELLforCURE by SEQENS, a Contract Development and Manufacturing Organization (CDMO) for...
Carlos Chattah Photography
9-Year Old Rare Blood Disorder Survivor Meets Lifesaving Donor at Gift of Life Marrow Registry Gala
November 22, 2024 15:37 ET | Gift of Life Marrow Registry
Miami Beach Event Honored Emilio Estefan, Jr., Vice Mayor Alex Fernandez and Boucher Brothers for their Distinguished Advocacy BOCA RATON, Fla., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Gift of Life...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
November 12, 2024 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
November 07, 2024 16:05 ET | Vor Biopharma
Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed as...
Smart Immune détermi
Smart Immune détermine la dose recommandée de SMART101 pour ses essais cliniques en oncologie
October 23, 2024 01:01 ET | Smart Immune
La phase I d'escalade de dose de ReSET-02 chez des adultes souffrant de cancers hématologiques est terminée.Le segment randomisé de la phase II de cet essai est en cours.Aucune toxicité limitant la...
SMART IMM_LOGO 2023_RVB.png
Smart Immune Announces Recommended SMART101 Dose for Adult Cancer Proof-of-Concept Trials
October 23, 2024 01:01 ET | Smart Immune
ReSET-02 dose escalation Phase I is completedPhase II PoC randomized segment is starting No dose-limiting toxicities, no safety or tolerability issuesThe highest dose is to be used in both...
Gift of Life Marrow Registry partners with Miami Beach Police and Fire Departments
Gift of Life Marrow Registry and Miami Beach First Responders Rally to Tackle the Shortage of Hispanic Donors for Blood Cancer Patients
October 11, 2024 13:27 ET | Gift of Life Marrow Registry
To combat the critical shortage of Hispanic donors, Gift of Life Marrow Registry has partnered with the Miami Beach Police and Fire Departments.
NMDP
NMDP℠ Raises $1.1 Million at Annual Gala Expanding Access to Life-Saving Cell Therapies
October 03, 2024 09:00 ET | NMDP
NMDP, a global nonprofit leader in cell therapy, raised $1.1 million during its 17th annual fundraising gala expanding access to life-saving treatments.
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
September 30, 2024 07:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new...